Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 8/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 2/20 | 0.32 |
| ▸ | USP10 | Q14694 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3176815 | 0.96 | CTSS (0.36) | CTSLCTSKCTSSCTSBSIGMAR1 | |
| SCHEMBL3954017 | 0.89 | CTSK (0.41) | CTSLCTSKCTSSCTSBSIGMAR1 | |
| SCHEMBL3165918 | 0.88 | CTSK (0.42) | CTSLCTSKCTSSCTSBSIGMAR1 | |
| SCHEMBL3168819 | 0.88 | CTSK (0.42) | CTSLCTSKCTSSCTSBSIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL3959334 | 0.87 | CTSL (0.38) | CTSLCTSKCTSSCTSBSIGMAR1 | |
| SCHEMBL3165113 | 0.86 | CTSS (0.46) | CTSLCTSKCTSSCTSBSIGMAR1 | |
| SCHEMBL3166608 | 0.86 | CTSS (0.47) | CTSLCTSKCTSSCTSBSIGMAR1 | |
| SCHEMBL3166033 | 0.86 | CTSK (0.41) | CTSLCTSKCTSSCTSBSIGMAR1 | |
| SCHEMBL3170053 | 0.86 | CTSL (0.38) | CTSLCTSKCTSSCTSBSIGMAR1 | |
| SCHEMBL3176722 | 0.86 | CTSK (0.43) | CTSLCTSKCTSSCTSBF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited , a corporation | 2010-01-14 | — | — | US | claimed |
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited , a corporation | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | SERPINB1, CTRL, PRSS1 | CTSL 9/4885CTSK 65/4885CTSS 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.